Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
Nautilus Biotechnology, a leader in single-molecule protein analysis, will participate in the B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics Virtual Conference on April 6, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology, a leader in single-molecule protein analysis, will participate in the B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics Virtual Conference on April 6, 2023. The management will feature in a fireside chat at 10:30 a.m. Pacific Time. Investors and interested individuals can tune in to a live and archived webcast on the company’s website. Nautilus aims to revolutionize proteomics by enhancing access to the proteome, fostering significant advancements in human health. To learn more, visit www.nautilus.bio.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was -2.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference.
Nautilus’ management is scheduled to participate in a fireside chat on Thursday, April 6th at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the company’s website on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.